Grant: Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
University of Toronto
$100,000.00
Glucocorticoid-induced osteoporosis: the role of G11 overexpression in osteoblasts
EF 2009-10
Résumé
Glucocorticoids are widely used drugs in the treatment of inflammatory diseases as well as some forms of cancer. Long-term use of these agents is limited by profound skeletal growth inhibition in children and osteoporosis in both children and adults. We are investigating the effects of glucocorticoids on bone to help suggest therapeutic interventions in patients receiving glucocorticoid therapy.
Work in my laboratory has shown that glucocorticoids alter the responses of osteoblasts (the cells that make bone) to a number of hormones and neurotransmitters by increasing the amount of G proteins (primarily G11 and to a lesser extent Gs) expressed in the cells. These G proteins transmit the signals from hormone and neurotransmitter receptors to intracellular pathways that alter cell growth and function. To understand the importance of these changes in G proteins we are creating mice in which the G proteins are over-expressed, mimicking the effects of the drugs. In this proposal our transgenic mouse line that over-expresses G11 is demonstrated to have decreased bone density and increased responses to hormones that regulate bone. The animals also show decreased differentiation and survival of osteoblasts taken from their bone marrow. All of these findings are consistent with the effects of glucocorticoids on bone and so we will use our transgenic mice to test 1) the specific molecular pathways that cause decreased survival of osteoblasts, 2) the response of the animals to osteoporosis therapies with bisphosphonates and intermittent PTH and 3) the effect of estrogen withdrawal and low calcium diet on bone density. In all of our experiments we will compare our transgenic mice to normal mice that are treated with glucocorticoids.
Together our studies will help us understand how glucocorticoids induce osteoporosis and begin to assess the response of the bones to therapies.
Programme
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
196418
Name
Mitchell Jane A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage
Projecttitle
Glucocorticoid-induced osteoporosis: the role of G11 overexpression in osteoblasts
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Keyworddelim
Bone; Cell Growth; Glucocorticoids; Osteoporosis; Parathyroid Hormone; Transcription Factors
Abstract
Glucocorticoids are widely used drugs in the treatment of inflammatory diseases as well as some forms of cancer. Long-term use of these agents is limited by profound skeletal growth inhibition in children and osteoporosis in both children and adults. We are investigating the effects of glucocorticoids on bone to help suggest therapeutic interventions in patients receiving glucocorticoid therapy.
Work in my laboratory has shown that glucocorticoids alter the responses of osteoblasts (the cells that make bone) to a number of hormones and neurotransmitters by increasing the amount of G proteins (primarily G11 and to a lesser extent Gs) expressed in the cells. These G proteins transmit the signals from hormone and neurotransmitter receptors to intracellular pathways that alter cell growth and function. To understand the importance of these changes in G proteins we are creating mice in which the G proteins are over-expressed, mimicking the effects of the drugs. In this proposal our transgenic mouse line that over-expresses G11 is demonstrated to have decreased bone density and increased responses to hormones that regulate bone. The animals also show decreased differentiation and survival of osteoblasts taken from their bone marrow. All of these findings are consistent with the effects of glucocorticoids on bone and so we will use our transgenic mice to test 1) the specific molecular pathways that cause decreased survival of osteoblasts, 2) the response of the animals to osteoporosis therapies with bisphosphonates and intermittent PTH and 3) the effect of estrogen withdrawal and low calcium diet on bone density. In all of our experiments we will compare our transgenic mice to normal mice that are treated with glucocorticoids.
Together our studies will help us understand how glucocorticoids induce osteoporosis and begin to assess the response of the bones to therapies.
Competitiondate
200909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mitchell, Jane A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~